Epitestosterone- and testosterone-replacement in immature castrated rats changes main testicular developmental characteristics.

Epitestosterone is the 17α-epimer of testosterone and has been described as an anti-androgen, since it inhibits the effects produced by testosterone and dihydrotestosterone via the nuclear androgen receptor (nAR). However, epitestosterone also displays an effect which is similar to the non-classical effect of testosterone, depolarizing the membrane potential of Sertoli cells and inducing a rapid Ca2+ uptake. This study aimed to investigate the effects of a treatment with epitestosterone on developmental parameters of immature rats. Animals were chemically castrated by using the gonadotropin-releasing hormone (GnRH) antagonist cetrorelix and then received a replacement of 7 days with epitestosterone or testosterone. Replacement with either epitestosterone or testosterone restored the anogenital distance (AGD) and testicular weight which had been reduced by chemical castration. The immunocontent of nAR and the nAR-immunoreactivity were reduced by epitestosterone treatment in the testis of both castrated and non-castrated animals. Furthermore, testosterone was unable of changing the membrane potential of Sertoli cells through its non-classical action in the group of animals castrated and replaced with epitestosterone. In conclusion, in relation to the level of protein expression of nAR epitestosterone acts as an anti-androgen. However, it acts in the same way as testosterone when genital development parameters are evaluated. Moreover, in castrated rats epitestosterone suppressed the non-classical response of testosterone, changing the pattern of testosterone signalling via a membrane mechanism in Sertoli cells.

[Premature ovarian failure: present aspects]. / Falência ovariana prematura: aspectos atuais.

Premature ovarian failure occurs in approximately 1:1000 women before 30 years, 1:250 by 35 years and 1:100 by the age of 40. It is characterized by primary or secondary amenorrhea and cannot be considered as definitive because spontaneous conception may occur in 5 to 10% of cases. In 95% of cases, premature ovarian failure is sporadic. The known causes of premature ovarian failure include chromosomal defects, autoimmune diseases, exposure to radiation or chemotherapy, surgical procedures, and certain drugs. Frequently, however, the etiology is not clear and these cases are considered to be idiopathic. Premature ovarian failure is defined by gonadal failure and high serum follicle-stimulating hormone (FSH) levels. Clinical approach includes emotional support, hormonal therapy with estrogens and progesterone or progestogens, infertility treatment, and prevention of osteoporosis and potential cardiovascular risk.

Falência ovariana prematura: aspectos atuais / Premature ovarian failure: present aspects

A falência ovariana prematura (FOP) acomete aproximadamente 1:1000 mulheres antes dos 30 anos, 1:250 em torno dos 35 anos e de 1:100 aos 40 anos. Manifesta-se como amenorréia primária ou amenorréia secundária, não podendo ser considerada definitiva em todas as pacientes, uma vez que a concepção espontânea pode ocorrer em até 5-10 por cento das FOP. Na maioria dos casos apresenta-se na forma esporádica, pois apenas 5 por cento apresentam história familial. Entre as causas conhecidas estão as alterações cromossômicas, dos genes ligados ao cromossomo X e cromossomos autossômicos, doenças autoimunes, alterações tóxicas e iatrogênicas. Com relativa freqüência, a causa etiológica não é obtida, sendo então denominada de idiopática. O diagnóstico da FOP é feito baseado na história clínica e níveis elevados do hormônio folículo estimulante (FSH), sendo posteriormente investigadas as causas mais específicas. O manejo clínico visa o suporte emocional, o tratamento hormonal com estrogênios e progestogênios, a abordagem da infertilidade e a prevenção de co-morbidades como a osteoporose e potencial maior risco cardiovascular.

Premature ovarian failure occurs in approximately 1:1000 women before 30 years, 1:250 by 35 years and 1:100 by the age of 40. It is characterized by primary or secondary amenorrhea and cannot be considered as definitive because spontaneous conception may occur in 5 to 10 percent of cases. In 95 percent of cases, premature ovarian failure is sporadic. The known causes of premature ovarian failure include chromosomal defects, autoimmune diseases, exposure to radiation or chemotherapy, surgical procedures, and certain drugs. Frequently, however, the etiology is not clear and these cases are considered to be idiopathic. Premature ovarian failure is defined by gonadal failure and high serum follicle-stimulating hormone (FSH) levels. Clinical approach includes emotional support, hormonal therapy with estrogens and progesterone or progestogens, infertility treatment, and prevention of osteoporosis and potential cardiovascular risk.

Absence of follicle-stimulating hormone receptor activating mutations in women with iatrogenic ovarian hyperstimulation syndrome.

OBJECTIVE: To analyze the FSH receptor gene in women with iatrogenic ovarian hyperstimulation syndrome (OHSS). DESIGN: Clinical and molecular studies. SETTING: University hospital and private clinic. PATIENT(S): Twenty-nine women who developed moderate or severe OHSS after ovulation induction for IVF. In addition, 50 fertile normal women were used as controls. INTERVENTION(S): Peripheral blood was used for DNA extraction. The exons 4, 7, 9, and 10 of the FSH receptor gene were amplified by polymerase chain reaction (PCR) followed by automatic direct sequencing. MAIN OUTCOME MEASURE(S): Hormonal results and automatic sequencing analysis. RESULT(S): Thirteen patients developed moderate OHSS and 16 patients developed the severe form of the syndrome. Automatic sequencing revealed no activating mutations in all patients studied. We found two known polymorphisms in linkage disequilibrium, Ala307Thr and Ser680Asn, in 79.3% of the patients (44.8% in heterozygous and 34.5% in homozygous state). These polymorphisms were found with similar frequency in the 50 normal fertile women. CONCLUSION(S): We conclude that the FSH receptor genotype did not play a significant role in the risk of iatrogenic OHSS in this cohort.

O papel dos receptores das gonadotrofinas na reproduçäo feminina / Role of gonadotropins receptors in female reproduction

As açöes fundamentais das gonadotrofinas hipofisárias na vida sexual reprodutiva de ambos os sexos dependem da integridade estrutural e funcional dos seus respectivos receptores, Os receptores das gonadotrofinas localizados na membrana citoplasmàtica säo membros da grande família dos receptores acoplados à proteína G e apresentam uma estrutura comum caracterizada por uma extensa porçäo extracelular e setes hélices transmembranas. A recente identificaçäo de mutaçöes inativadoras e ativadoras de ocorrência natural nos genes dos receptores do LH e do FSH contribuíram para a maior compreensäo de estados patológicos gonadais. Neste trabalho, revisamos os aspectos moleculares dos defeitos dos genes dos receptores das gonadotrofinas e suas implicaçöes fenotípicas no sexo feminino. Nas mulheres com mutaçöes inativadoras em homozigose nestes genes, sintomas freqüentes como alteraçöes menstruais (amenorréia secundária e oligoamenorréia) e infertilidade podem alertar o endocrinologista para o estabelecimento do diagnõsti-co definitivo da resistência ovariana ao LH ou ao FSH.

Male pseudohermaphroditism due to 5 alpha reductase deficiency associated with gynecomastia

Os autores apresentaram três casos de ambigüidade genital por deficiência de 5 alfa-reductase, diagnosticada pelos níveis elevados da relaçäo T/DHT. Os pacientes mais jovens apresentaram ginecomastia leve (Tanner II), ainda näo descrita nesta síndrome. Concluimos que o desenvolvimento de ginecomastia leve pode ocorrer no pseudo-hermafroditismo por deficiência de 5 alfa-reductase

Níveis basais das gonadotrofinas (LH e FSH), prolactina e testosterona em pacientes urêmicos mantidos em hemodiálise / Basal levels of gonadotropin (LH and FSH), prolactin and testosterone in uremic patients mantained in hemodialysis

Avaliaram-se os níveis de LH, FSH, PRL e T em 24 pacientes urêmicos mantidos em hemodiálise. Observaram-se níveis elevados de LH e PRL em 64 e 67% dos pacientes, respectivamente, com níveis normais de FSH em 20% dos pacientes e níveis baixos de T em apenas 8% dos pacientes. Concluiu-se que níveis elevados de LH näo caracterizam lesäo testicular primária nestes pacientes, mas sim alteraçäo transitória do sistema hipotálamo-hipófise-testículo, induzida pela uremia